Exicure Inc: Rises on FDA orphan drug tag for skin cancer treatment

Exicure

03/03/2021 12:58

** Shares of biotechnology firm  XCUR.O  rise 5.7% to $2.40
premarket
    ** XCUR says the U.S. FDA granted orphan drug designation
for its product candidate, cavrotolimod, to treat Merkel cell
carcinoma (MCC) -  a rare type of skin cancer  urn:newsml:reuters.com:*:nBw31nQ51a
    ** Orphan status is granted to treatments for rare diseases
or disorders that affect fewer than 200,000 people in the United
States
    ** Co in January said the FDA granted fast track designation
to cavrotolimod for developmental programs in MCC and another
type of skin cancer  urn:newsml:reuters.com:*:nL4N2JM2E8
    ** XCUR had gained 28.3% YTD, as of its last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))